NASDAQ:AMED - Amedisys Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$108.21 -0.02 (-0.02 %)
(As of 10/22/2018 12:55 PM ET)
Previous Close$108.23
Today's Range$108.21 - $110.32
52-Week Range$45.60 - $127.38
Volume7,040 shs
Average Volume401,605 shs
Market Capitalization$3.45 billion
P/E Ratio49.21
Dividend YieldN/A
Beta1
Amedisys, Inc., together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks. The Hospice segment offers care that is designed to provide comfort and support for those who are dealing with a terminal illness, including heart disease, pulmonary disease, Alzheimer's, HIV/AIDS, and cancer. The Personal Care segment provides assistance for patients with the activities of daily living. As of February 27, 2018, the company owned and operated 421 care centers in 34 states. Amedisys, Inc. was founded in 1982 and is headquartered in Baton Rouge, Louisiana.

Receive AMED News and Ratings via Email

Sign-up to receive the latest news and ratings for AMED and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:AMED
CUSIP02343610
Phone225-292-2031

Debt

Debt-to-Equity Ratio0.30
Current Ratio1.21
Quick Ratio1.21

Price-To-Earnings

Trailing P/E Ratio49.21
Forward P/E Ratio31.73
P/E Growth1.64

Sales & Book Value

Annual Sales$1.53 billion
Price / Sales2.25
Cash Flow$2.7626 per share
Price / Cash39.17
Book Value$15.22 per share
Price / Book7.11

Profitability

EPS (Most Recent Fiscal Year)$2.21
Net Income$30.30 million
Net Margins4.46%
Return on Equity20.11%
Return on Assets12.46%

Miscellaneous

Employees17,900
Outstanding Shares31,840,000
Market Cap$3.45 billion

Amedisys (NASDAQ:AMED) Frequently Asked Questions

What is Amedisys' stock symbol?

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

How were Amedisys' earnings last quarter?

Amedisys Inc (NASDAQ:AMED) announced its quarterly earnings data on Tuesday, July, 31st. The health services provider reported $1.00 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.78 by $0.22. The health services provider earned $411.60 million during the quarter, compared to the consensus estimate of $403.62 million. Amedisys had a net margin of 4.46% and a return on equity of 20.11%. During the same quarter last year, the firm earned $0.62 earnings per share. View Amedisys' Earnings History.

When is Amedisys' next earnings date?

Amedisys is scheduled to release their next quarterly earnings announcement on Monday, October 29th 2018. View Earnings Estimates for Amedisys.

How can I listen to Amedisys' earnings call?

Amedisys will be holding an earnings conference call on Tuesday, October 30th at 11:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8775248416.

What guidance has Amedisys issued on next quarter's earnings?

Amedisys updated its FY18 earnings guidance on Tuesday, July, 31st. The company provided EPS guidance of $3.32-3.41 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.11. The company issued revenue guidance of $1.63-1.65 billion, compared to the consensus revenue estimate of $1.63 billion.

What price target have analysts set for AMED?

13 equities research analysts have issued 12 month price objectives for Amedisys' stock. Their forecasts range from $56.00 to $139.00. On average, they expect Amedisys' stock price to reach $96.6667 in the next year. This suggests that the stock has a possible downside of 10.7%. View Analyst Price Targets for Amedisys.

What is the consensus analysts' recommendation for Amedisys?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 5 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amedisys.

Are investors shorting Amedisys?

Amedisys saw a increase in short interest in September. As of September 14th, there was short interest totalling 1,979,938 shares, an increase of 111.4% from the August 31st total of 936,780 shares. Based on an average daily volume of 341,548 shares, the days-to-cover ratio is presently 5.8 days. Currently, 6.3% of the shares of the company are short sold. View Amedisys' Current Options Chain.

Who are some of Amedisys' key competitors?

Who are Amedisys' key executives?

Amedisys' management team includes the folowing people:
  • Mr. Paul Berthold Kusserow, Pres, CEO & Director (Age 57)
  • Mr. Scott G. Ginn, Chief Financial Officer (Age 49)
  • Mr. Christopher T. Gerard, Chief Operating Officer (Age 51)
  • Mr. Michael P. North, Chief Information Officer (Age 53)
  • Mr. Pete Hartley, CTO & Sr. VP of Bus. Operations Systems

Who are Amedisys' major shareholders?

Amedisys' stock is owned by many different of institutional and retail investors. Top institutional shareholders include MERIAN GLOBAL INVESTORS UK Ltd (0.13%), Nisa Investment Advisors LLC (0.10%), Aperio Group LLC (0.06%), DNB Asset Management AS (0.05%), Strs Ohio (0.04%) and Mitsubishi UFJ Asset Management UK Ltd. (0.03%). Company insiders that own Amedisys stock include Bruce D Perkins, David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Lawrence R Pernosky, Michael Paul North and Scott G Ginn. View Institutional Ownership Trends for Amedisys.

Which institutional investors are selling Amedisys stock?

AMED stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Seven Eight Capital LP, Mitsubishi UFJ Asset Management UK Ltd. and Strs Ohio. Company insiders that have sold Amedisys company stock in the last year include David B Pearce, David L Kemmerly, Jake L Netterville, Jeffrey A Rideout, Kkr Credit Advisors (Us) Llc, Michael Paul North and Scott G Ginn. View Insider Buying and Selling for Amedisys.

Which institutional investors are buying Amedisys stock?

AMED stock was bought by a variety of institutional investors in the last quarter, including MERIAN GLOBAL INVESTORS UK Ltd, Nisa Investment Advisors LLC, Bowling Portfolio Management LLC, Bfsg LLC and Aperio Group LLC. View Insider Buying and Selling for Amedisys.

How do I buy shares of Amedisys?

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amedisys' stock price today?

One share of AMED stock can currently be purchased for approximately $108.21.

How big of a company is Amedisys?

Amedisys has a market capitalization of $3.45 billion and generates $1.53 billion in revenue each year. The health services provider earns $30.30 million in net income (profit) each year or $2.21 on an earnings per share basis. Amedisys employs 17,900 workers across the globe.

What is Amedisys' official website?

The official website for Amedisys is http://www.amedisys.com.

How can I contact Amedisys?

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]


MarketBeat Community Rating for Amedisys (NASDAQ AMED)

Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  265 (Vote Outperform)
Underperform Votes:  428 (Vote Underperform)
Total Votes:  693
MarketBeat's community ratings are surveys of what our community members think about Amedisys and other stocks. Vote "Outperform" if you believe AMED will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMED will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel